APPLICATION FORM
CHRONIC MEDICATION MANAGEMENT

GENERAL INFORMATION

TO BE COMPLETED BY THE APPLICANT

MEMBER DETAILS:

Option

Membership number

Surname

Title Initials

Email address

PATIENT DETAILS:

Name and surname

Title ID number

Address

Code

Email address

Telephone numbers Home Work

Cell phone

I authorise my medical practitioner to furnish and/or disclose to the Chronic Medication Management Programme any fact relating to this application as well as any additional information that may be required from time to time. (Remember that your medical practitioner bears the responsibility of prescribing the medication for you, irrespective of the benefit authorised).

Member's signature _____ Date D D M M Y Y Y Y

TO BE COMPLETED BY THE ATTENDING MEDICAL PRACTITIONER

DOCTOR DETAILS:

Surname Initials

Practice number

Provider discipline

Telephone numbers Work Fax

Cell phone

Postal address

Code

Email address

GENERAL INFORMATION (CONTINUED)

TO BE COMPLETED BY THE ATTENDING MEDICAL PRACTITIONER (CONTINUED)

ASSOCIATED SPECIALIST DETAILS:

Name

Practice number

Speciality

CLINICAL EXAMINATION:

Gender ☐ M ☐ F Weight ☐☐☐ kg Height ☐☐☐ cm Blood pressure ☐☐☐ ☐☐☐

Smoking	☐ Never	☐ Ex-smoker	☐ <10 per day	☐ <10 per day
Exercise	☐ Never	☐ <1 hour per week	☐ 1-3 hours per week	☐ >3 hours per week
Allergies	☐ Penicillin	☐ Aspirin	☐ Sulphonamides	

Other

The Chronic Medication Management Programme requires certain special investigations to expedite the chronic authorisation process. This includes, but is not limited to, the following:

» Angiotensin receptor blockers (ARBs):	Motivation
» Bisphosphates and other agents for osteoporosis:	Bone mineral density and motivation
» Chronic obstructive airways disease:	Lung function tests
» Chronic renal failure:	Creatinine clearance/glomerular filtration rate
» Haemophilia:	Factors VIII and IX blood levels
» Hyperlipidaemia:	Lipogram*
» Long-acting insulin analogues, glitazones:	HbA_{1c} and motivation

* In primary prevention patients requesting lipid-modifying therapy (e.g. statins), reimbursement is reserved for patients with a greater than 20% risk of an acute clinical coronary event within the next 10 years, as calculated by the Framingham Risk Calculation and in accordance with locally and internationally accepted treatment guidelines.

Please indicate below where you agree to a generic substitution and provide your preferred medication name. Chronic medication is subject to generic reference pricing.

MEDICATION PRESCRIBED (PLEASE USE BLOCK LETTERS)

ICD-10 code(s)	Detailed diagnosis and date of diagnosis	Name (trade name or generic equivalent)	Generic substitution		Strength (e.g. 50mg)	Directions (e.g. 2tds)	Date medication started	Type and date of investigation/report
			Yes	No				

Membership no. ☐☐☐☐☐☐☐☐☐☐☐☐☐ Doctor's practice no. ☐☐☐☐☐☐☐☐☐☐☐☐☐

MEDICATION STOPPED (PLEASE USE BLOCK LETTERS)

ICD-10 code(s)	Diagnosis	Name (trade name or generic equivalent)	Strength (e.g. 50mg)	Directions (e.g. 2tds)	Date medication stopped

PRESCRIBED MINIMUM BENEFITS

If your patient has one or more of the following chronic conditions, he or she may qualify for additional services. Please indicate which condition(s) he or she has by placing an 'X' next to the applicable condition.

	Addison's disease		Crohn's disease		Hypertension
	Asthma		Diabetes insipidus		Hypothyroidism
	Bipolar mood disorder		Diabetes mellitus type 1		Multiple sclerosis
	Bronchiectasis		Diabetes mellitus type 2		Parkinson's disease
	Cardiac failure		Dysrhythmias		Rheumatoid arthritis
	Cardiomyopathy disease		Epilepsy		Schizophrenia
	Chronic obstructive pulmonary disorder		Glaucoma		Systemic lupus erythematosus
	Chronic renal disease		Haemophilia		Ulcerative colitis
	Coronary artery disease		Hyperlipidaemia		

ADDITIONAL CONDITIONS (INCLUDING PMB DTP CONDITIONS)

In addition to all the conditions on the PMB list, members will also be covered for the following conditions:

	Allergic rhinitis		Huntington's disease
	Ankylosing spondylitis		Hyperthyroidism
	Aplastic anaemia		Hypoparathryroidism
	Attention deficit hyperactivity disorder (ADHD)		Menopause
	Cryoglobulinemia		Motor neuron disease
	Cystic fibrosis		Muscular dystrophy and other inherited myopathies
	Cystic nodular acne		Myasthenia gravis
	Deep vein thrombosis		Myelodysplastic anaemia
	Depression		Narcolepsy
	Dermatitis (eczema)		Obsessive compulsive disorder
	Dermatomyositis		Osteoporosis
	Dystonia		Paget's disease
	Eating disorders		Para-/quadriplegia
	Endocarditis		Pemphigus
	Gastro-oesophageal reflux disease (GORD)		Peptic ulcers

Continued overleaf »

Membership no. | | | | | | | | | | |

Doctor's practice no. | | | | | | | | | | | | |

PRESCRIBED MINIMUM BENEFITS (CONTINUED)

ADDITIONAL CONDITIONS (INCLUDING PMB DTP CONDITIONS) (CONTINUED)

	Pituitary gland disorders (hypo- and hyperfunction)		Stroke (haemorrhage or infarction)
	Post-myocardial infarction		Systemic sclerosis
	Psoriasis		Thrombocytopenia
	Pulmonary interstitial fibrosis		Tic disorders
	Scleroderma		Valvular heart disease
	Sjogren's syndrome		

PATIENT CONSENT

I hereby acknowledge that the Scheme has appointed Momentum Health Solutions (Pty) Ltd as the administrator of the programme and that any prescribed medical treatment shall be the sole responsibility of my medical practitioner.

I understand that the information provided on this form shall be treated as confidential and will not be used or disclosed except for the purpose for which it has been obtained.

I hereby give my consent to Momentum Health Solutions and its staff to obtain my special personal information (i.e. health and biometric) from my healthcare providers (pharmacy, pathology, medical doctor and radiology) to assess my medical risk and enrol me on the programme and to use such information to my benefit. I understand and agree that special personal information relevant to my current state of health can be disclosed to third parties for the purpose of scientific, epidemiological and/or financial analysis without disclosure of my identity.

Whilst Momentum Health Solutions undertakes to take all reasonable precautions to uphold the confidentiality of information disclosed to it, I am aware that the Scheme and practitioner (where necessary) shall also gain access to the same information. I shall therefore not hold Momentum Health Solutions liable for any claims by me or my dependants arising from any unauthorised disclosure of my special personal information to other parties.

I hereby certify that the information provided is true and correct.

Member's signature	Prescribing doctor's signature	D D M M Y Y Y Y Date

Membership no. | | | | | | | | | | |

Doctor's practice no. | | | | | | | | | | | | |

03/2020

Return address: Chronic Medication Management Programme, PO Box 32759, Braamfontein 2017
Tel 0860 467 374 **Fax** 0860 111 788 **Email** chronic@imperialmotusmed.co.za